Immune-Mediated Necrotizing Myopathy Associated With Anti-signal Recognition Particle Antibody Complicated With Acute Respiratory Distress Syndrome: A Report of Two Cases

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Jun 17

PMID 38883031

Authors

Da-Wei Fang

Yi-Min Chen

Affiliations

Soon will be listed here.

Abstract

Immune-mediated necrotizing myopathy (IMNM) represents a rare category of inflammatory myopathies characterized by more severe and rapid progression of symmetrical proximal muscle weakness. It is also marked by notably elevated serum muscle enzyme levels and distinct histological features, setting it apart from other types of myositis. Moreover, acute chronic lung respiratory dysfunction is a major comorbidity of great concern. We herein present two cases of IMNM associated with anti-signal recognition particle antibodies complicated by acute respiratory distress syndrome.

References

Suzuki S, Nishikawa A, Kuwana M, Nishimura H, Watanabe Y, Nakahara J . Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis. 2015; 10:61. PMC: 4440264. DOI: 10.1186/s13023-015-0277-y. View

Pinal-Fernandez I, Mammen A . Spectrum of immune-mediated necrotizing myopathies and their treatments. Curr Opin Rheumatol. 2016; 28(6):619-24. PMC: 11669099. DOI: 10.1097/BOR.0000000000000335. View

Yang H, Tian X, Jiang W, Li W, Liu Q, Peng Q . [Clinical and pathological characteristics of immune mediated necrotizing myopathy]. Beijing Da Xue Xue Bao Yi Xue Ban. 2019; 51(6):989-995. PMC: 7433591. View

Allenbach Y, Mammen A, Benveniste O, Stenzel W . 224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord. 2017; 28(1):87-99. DOI: 10.1016/j.nmd.2017.09.016. View

Arlet J, Dimitri D, Pagnoux C, Boyer O, Maisonobe T, Authier F . Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord. 2006; 16(5):334-6. DOI: 10.1016/j.nmd.2006.03.002. View

Luo Y, Mastaglia F . Dermatomyositis, polymyositis and immune-mediated necrotising myopathies. Biochim Biophys Acta. 2014; 1852(4):622-32. DOI: 10.1016/j.bbadis.2014.05.034. View

Kim S, Park I . Acute Respiratory Distress Syndrome as the Initial Clinical Manifestation of an Antisynthetase Syndrome. Tuberc Respir Dis (Seoul). 2016; 79(3):188-92. PMC: 4943904. DOI: 10.4046/trd.2016.79.3.188. View

Watanabe Y, Uruha A, Suzuki S, Nakahara J, Hamanaka K, Takayama K . Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry. 2016; 87(10):1038-44. DOI: 10.1136/jnnp-2016-313166. View

Khan M, Patel A, Pendharkar S . Anti-signal Recognition Particle Necrotizing Autoimmune Myopathy: An Atypical Presentation. Cureus. 2019; 10(12):e3766. PMC: 6389032. DOI: 10.7759/cureus.3766. View

10.

Kusumoto T, Okamori S, Masuzawa K, Asakura T, Nishina N, Chubachi S . Development of Necrotizing Myopathy Following Interstitial Lung Disease with Anti-signal Recognition Particle Antibody. Intern Med. 2018; 57(14):2045-2049. PMC: 6096015. DOI: 10.2169/internalmedicine.0303-17. View

11.

Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L . Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken). 2010; 62(9):1328-34. PMC: 3107255. DOI: 10.1002/acr.20219. View

12.

Shappley C, Paik J, Saketkoo L . Myositis-Related Interstitial Lung Diseases: Diagnostic Features, Treatment, and Complications. Curr Treatm Opt Rheumatol. 2020; 5(1):56-83. DOI: 10.1007/s40674-018-0110-6. View

13.

Pinal-Fernandez I, Parks C, Werner J, Albayda J, Paik J, Danoff S . Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle. Arthritis Care Res (Hoboken). 2016; 69(2):263-270. PMC: 5079847. DOI: 10.1002/acr.22920. View

14.

Lundberg I, Miller F, Tjarnlund A, Bottai M . Diagnosis and classification of idiopathic inflammatory myopathies. J Intern Med. 2016; 280(1):39-51. PMC: 5021058. DOI: 10.1111/joim.12524. View

15.

Day J, Limaye V . Immune-mediated necrotising myopathy: A critical review of current concepts. Semin Arthritis Rheum. 2019; 49(3):420-429. DOI: 10.1016/j.semarthrit.2019.04.002. View

16.

Weeding E, Tiniakou E . Therapeutic management of immune-mediated necrotizing myositis. Curr Treatm Opt Rheumatol. 2021; 7(2):150-160. PMC: 8378663. DOI: 10.1007/s40674-021-00174-1. View

17.

Bedrossian C, Sussman J, Conklin R, Kahan B . Azathioprine-associated interstitial pneumonitis. Am J Clin Pathol. 1984; 82(2):148-54. DOI: 10.1093/ajcp/82.2.148. View

18.

Naqibullah M, Shaker S, Bach K, Bendstrup E . Rituximab-induced interstitial lung disease: five case reports. Eur Clin Respir J. 2015; 2. PMC: 4629765. DOI: 10.3402/ecrj.v2.27178. View